Macular oedema controlled by Avastin?

Article

Bevacizumab injections can improve vision in patients with diabetic macular oedema, according to study results published in the October 2008 issue of the journal Retina.

Bevacizumab injections (Avastin) can improve vision in patients with diabetic macular oedema (DME), according to study results published in the October 2008 issue of the journal Retina.

Mi In Roh, MD of Yonsei University College of Medicine, Seoul, Korea and colleagues administered repeated injections of intravitreal bevacizumab (at a mean interval of 22.06±11.15 weeks) to eyes presenting with clinically significant macular oedema (n=31), and measured visual acuity (VA) and biological data before the first injection, as well as at one, six and 12 weeks after the injection. They then compared these results with those obtained from independent and paired t-test groups.

The team reported that there were no statistically significant differences in VA and central macular thickness (CMT) values between the groups before the bevacizumab injections. Six weeks after the initial injection, VA increased by 3.72±8.02 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart; CMT decreased by 93.30±210.33 µm at six weeks, which, at 12 weeks, returned to baseline levels. After the second injection, VA increased by 3.97±7.46 letters and CMT decreased by 118.77±178.58 µm. At 12 weeks, VA had once again decreased and CMT had returned to oedematous levels.

Thus the team concluded that bevacizumab injections may improve both VA and CMT in eyes with diabetic macular oedema (DME). The effects are, however, short-lived, and therefore repeated injections are required to ensure long-term efficacy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.